Duvelisib was the second PI3K inhibitor authorised from the FDA, also depending on a stage III randomized trial.a hundred thirty The efficacy and security profile on the drug look similar with those of idelalisib, if not slightly advantageous. With regards to option BTK inhibitors, there are several products in development, but only acalabrutinib i